Starting with over 3,500 Canadian stocks, our research uncovers over 60 Small to-Micro Cap stocks – all profitable, cash rich (no debt) companies, many with between 10-100% of their market caps in cash. We drill down on each providing fundamental statistics and research notes from our management interviews and provide a select number of NEW BUY Reports. Flash Updates with current BUYS|SELL|HOLD ratings on all Cash Rich Stocks currently in coverage. New buy recommendations include 2 high growth software Small-Caps, one low-priced Micro-Cap and bonus notes on our recent Specialty Pharmaceutical selection which trades at a significant discount to its peers. The report has become an annual must read for growth and value investors and with 16 stocks receiving premium takeover bids it serves as an excellent source of potential takeover targets.Unique research you can find nowhere else. Last year’s Top Cash Rich recommendation Cipher Pharmaceuticals (CPH:TSX), has gained over 155% – do not miss out on this year’s recommendations.
2015 Cash Rich/Debt Free, Profitable Canadian Micro to Mid-Cap Report
$590.00
Description
Starting with over 3,500 Canadian stocks, our research uncovers over 60 Small to-Micro Cap stocks – all profitable, cash rich (no debt) companies, many with between 10-100% of their market caps in cash. We drill down on each providing fundamental statistics and research notes from our management interviews and provide a select number of NEW BUY Reports. Flash Updates with current BUYS|SELL|HOLD ratings on all Cash Rich Stocks currently in coverage. New buy recommendations include 2 high growth software Small-Caps, one low-priced Micro-Cap and bonus notes on our recent Specialty Pharmaceutical selection which trades at a significant discount to its peers. The report has become an annual must read for growth and value investors and with 16 stocks receiving premium takeover bids it serves as an excellent source of potential takeover targets.Unique research you can find nowhere else. Last year’s Top Cash Rich recommendation Cipher Pharmaceuticals (CPH:TSX), has gained over 155% – do not miss out on this year’s recommendations.
